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The objective of this study was to investigate the prevalence of Candida species in
HIV-infected African females and to compare their colonization to susceptibility patterns
and other parameters that may be distinguishing in women.
Approval from Ministry of Health Regional Hospital Institutional Review Board (IRB) in
Cameroon and from the Ethics Committee at the University of the Western Cape was
obtained. Patients presenting with white pseudomembranous plaque on the tongue or
other visible oral candidiasis were selected. Sterile oral swabs were used to collect a
sample from the affected areas in 194 HIV-positive women. Patients were required to
sign consent forms and to submit some personal information in a questionnaire. Data
from the patient’s hospital file was also collected.
Swabs were plated onto Sabouraud’s agar and grown at 30˚C on Fluka chromogenic
Candida identification agar and Oxoid chromogenic Candida agar [2]. Confirmation of
Candida species was achieved using microscopy, Gram staining and the germ tube
test. Presumptive C. albicans and C. dubliniensis isolates were differentiated by growth
at 37˚C for 48 hours in Tomato (V8) agar [3]; at 28˚C for 48-72 hours in Tobacco agar
[4] and at 45˚C for 24-48 hours in Sabouraud dextrose agar [5]. Differences in growth,
colony morphology and pseudohyphae/chlamydospore expression, allowed for species
identification.
Drug susceptibility testing to azole (fluconazole, itraconazole and voriconazole) and
echinocandin (anidulafungin, caspofungin and micafungin) drugs was done using the
TREK Sensititre YeastOne 9 (YO9) system (Thermo Scientific, USA), a CLSI-approved
broth micro-dilution method that allows for susceptibility testing of multiple antifungal
drugs [6,7]. An isolate was considered to be resistant if it fell within the established
“resistant” breakpoint category for one or more of the tested drugs in that class.
Statistical analysis for the species differentiation and susceptibility associations was
done by Pearson Chi-square and Fisher’s exact test using SPSS Version 21.0
(significant association: p<0.05).
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One of the most common HIV-associated opportunistic infections is candidiasis, caused
by the pseudohyphae-forming yeast of the Candida genus. These can cause an
increase in patient morbidity and mortality due to oropharyngeal or systemic
dissemination.
Candida is known to bind to the oral epithelial cells in women due to hormonal shifts
during the menstrual cycle and the contraceptive pill. Seropositive women have been
shown to have a higher oral colonization of Candida species, which increases with
higher HIV viral loads. The oral colonization of Candida species in women has been
reported to shift from C. albicans to non-albicans species over time and after antifungal
therapy.
The introduction of highly active anti-retroviral therapy (HAART) did not greatly reduce
the number of Candida infections over time, possibly due to antifungal prophylaxis over
the years and consequent increase in non-albicans resistant species [1].
The colonization and resistance patterns of Candida species in HIV-positive women
and their association with factors such as HAART, pregnancy, hormonal shifts, health
status and drug resistance patterns have not been previously described. This deserves
further investigation, as the presence of drug-resistant and non-albicans Candida
species could seriously affect the wellbeing of these patients.
Introduction: Sub-Saharan Africa has 23.5 million cases of HIV and is home to 92% of
the world’s HIV-positive pregnant women of whom 24% die of pregnancy related
complications. Oral candidiasis is a common condition in HIV-AIDS patients, caused by
commensal yeasts which may colonise the mucous membranes of the mouth causing
morbidity due to several factors including immunosuppression, smoking, poor nutrition
and the use of antibiotics.
Methods: One hundred and ninety-four South African and Cameroonian HIV-positive
women participated in the study. Only subjects who had white pseudomembranous
plaque on the tongue or visible oral candidiasis were included. Samples were collected
by scraping the patient’s oral mucosa and tongue with a sterile swab. Candida species
were differentiated using selective and chromogenic media and their susceptibility to
antifungal drugs was tested using the TREK Sensititre system.
Results and conclusion: One hundred and ninety-six isolates, representative of six
Candida species were identified. C. albicans was the predominating species, with C.
glabrata and C. dubliniensis being the more frequent of the non-albicans isolates. Azole
drug resistance patterns were very high for C. albicans, while C. glabrata showed high
resistance patterns to echinocandins drugs. The duration of ART could be associated
with the presence of different Candida species but no concrete conclusions could be
drawn concerning HIV/Candida co-infection when controlling for other risk factors such
as HIV stage, pregnancy, age and treatment for tuberculosis. This may be a cause for
concern, particularly in the case of pregnancy, where co-infection may pose a risk for
maternal morbidity and mortality.
The high levels of antifungal drug resistance seen in this cohort of women is worrying
and deserves further attention, especially since the drug of choice for Candida
infections in the African continent (fluconazole) was found to be ineffective against a
large amount of clinical Candida isolates. This is also a cause of concern due to the
fact that only albicans species (which expressed the highest resistance levels to
azoles) were found in pregnant mothers, which could pose a risk for pre-term delivery
and maternal morbidity and mortality [8].
The shift from C. albicans to the more drug-resistant non-albicans species seen after
continued ART is also a cause of concern that has not been previously documented.
We propose better monitoring of these patients, as the emergence on non-albicans
species and the empirical dispensation of antifungal drugs in resource-limited
healthcare facilities might not be effective in treating Candida infections in these
populations.
Out of the total 196 Candida strains isolated from the oral mucosa of 194 HIV-positive
females, 152 were identified as C. albicans, 27 as C. glabrata, 8 as C. dubliniensis, 4
as C. krusei, 3 as C. tropicalis and 2 as either C. parapsilopsis, C. lusitaneae or C.
kefyr. Two women were colonized by both C. albicans and C. glabrata.
Resistance to azole drugs was very high in the case of C. albicans (54%) and C.
krusei (100%). High levels of resistance to echinocandin drugs was seen in the case
of C. glabrata (40.7%), with only 2 (1.3%) of C. albicans isolates expressing
resistance to this class of drugs.
No associations were seen between Candida species prevalence and age or health
status. It was noted, however, that C. albicans was the only species isolated from the
oral mucosa of patients who were either pregnant or had recently given birth.
Patients who had not yet started ARV medication were mostly colonized by C.
albicans. However, a shift to non-albicans species was noted, as higher numbers of
non-albicans species were seen in patients who were on ARV therapy for longer
periods.
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C. albicans C. dubliniensis C. glabrata C. tropicalis C. krusei * C. kefyr/para/lusi p-
values
(n=152) (n=8) (n=27) (n=3) (n=4) (n=2)
Age distribution
10-20yrs (n=3) 3(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
21-50yrs (n=163) 127(77.9%) 8(4.9%) 21(12.9%) 2(1.2%) 4(2.4%) 1(0.6%)
>50yrs (n=30) 22(73.3%) 0(0%) 6(20%) 1(3.3%) 0(0%) 1(3.3%)
Health status
AIDS - (n=147) 112(76.2%) 8(5.4%) 20(13.6%) 2(1.4%) 3(2%) 2(1.4%)
AIDS + (n=49) 40(81.6%) 0(0%) 7(14.3%) 1(2%) 1(2%) 0(0%)
Pregnancy
Not pregnant (n=182) 138(75.8%) 8(4.4%) 27(14.8%) 3(1.6%) 4(2.2%) 2(1.1%)
Pregnant/recent birth 
(n=14)
14(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
Patients on TB treatment
No (n=172) 133(77.3%) 8(4.7%) 24(14%) 2(1.2%) 3(1.7%) 2(1.2%)
Yes (n=24) 19(79.2%) 0(0%) 3(12.5%) 1(8.3%) 1(8.3%) 0(0%)
ARV therapy
No ARV therapy (n=35) 30(85.7%) 2(5.7%) 2(5.7%) 1(2.9%) 0(0%) 0(0%)
AZT/NVP/3TC (n=73) 57(78.1%) 0(0%) 13(17.9%) 0(0%) 3(4.1%) 0(0%)
d4T/NVP/3TC (n=31) 21(67.7%) 3(9.7%) 5(16.1%) 0(0%) 1(3.2%) 1(3.2%)
d4T/EFV/3TC (n=24) 22(91.7%) 1(4.2%) 1(4.2%) 0(0%) 0(0%) 0(0%)
AZT/EFV/3TC (n=17) 13(76.5%) 0(0%) 3(17.6%) 1(5.9%) 0(0%) 0(0%)
LPV/r combinations 
(n=5)
3(60%) 1(20%) 1(20%) 0(0%) 0(0%) 0(0%)
AZT/DDI/KLT (n=3) 1(33.3%) 1(33.3%) 1(33.3) 0(0%) 0(0%) 0(0%)
TDF/3TC (n=2) 2(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
AZT/3TC/lopinavir/riton
avir (n=1)
0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1(100%)
AZT/3TC/KLT (n=1) 1(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
Not known (n=4) 2(50%) 0(0%) 1(25%) 1(25%) 0(0%) 0(0%)
Duration of ARV therapy
No ARV therapy (n=35) 30(85.7%) 2(5.7%) 2(5.7%) 1(2.9%) 0(0%) 0(0%) p=0.008
<1yr (n=50) 43(86%) 1(2%) 6(12%) 0(0%) 0(0%) 0(0%)
≥1-<3yrs (n=49) 35(71.4%) 5(10.2%) 7(14%) 1(2%) 1(2%) 0(0%)
≥3yrs (n=60) 44(73.3%) 0(0%) 11(18.3%) 0(0%) 3(5%) 2(3.3%)
Unknown (n=2) 0(0%) 0(0%) 1(50%) 1(50%) 0(0%) 0(0%)
Susceptibility patterns Susceptible Resistant Susceptible Resistant Susceptible Resistant Susceptible Resistant Susceptible Resistant Susceptible Resistant
Azoles 70(46%) 82(54%) 7(87.5%) 1(12.5%) 22(81.5%) 5(18.5%) 3(100% 0(0%) 0(0%) 3(100%) 2(100%) 0(0%) p=0.000
Echinocandins 150(98.7%) 2(1.3%) - - 16(59.3%) 11(40.7%) 3(100%) 0(0%) 3(100%) 0(0%) - - p=0.000
*One of the C. krusei isolates did not grow on the TREK plate, and was therefore not included in the susceptibility section of this table.
“-” = no established breakpoint for the organism/drug.
Table 1: Drug susceptibility and association results of Candida isolates.
